Literature DB >> 24857584

Nonfunctional pancreatic neuroendocrine tumors.

Jennifer H Kuo1, James A Lee2, John A Chabot1.   

Abstract

Pancreatic neuroendocrine tumors are a group of rare, heterogeneous neoplasms that have been increasing in incidence the past few decades largely because of the diagnosis of pancreatic incidentalomas on cross-sectional imaging. Although these tumors are classically associated with clinical syndromes that result from excess secretion of particular hormones, most pancreatic neuroendocrine tumors are nonfunctional tumors presenting with symptoms secondary to mass effect, metastatic disease, or as incidental findings. This article reviews the diagnostic algorithm, surgical management, and available systemic therapies for nonfunctional pancreatic neuroendocrine tumors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neuroendocrine; Neuroendocrine liver metastases; Nonfunctional; PanNET; Pancreas

Mesh:

Year:  2014        PMID: 24857584     DOI: 10.1016/j.suc.2014.02.010

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  16 in total

1.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

Review 2.  Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; James R Howe
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

Review 3.  Pancreatic neuroendocrine tumors.

Authors:  Jian Sun
Journal:  Intractable Rare Dis Res       Date:  2017-02

Review 4.  Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection.

Authors:  Paige Finkelstein; Rishika Sharma; Omar Picado; Rahul Gadde; Heather Stuart; Caroline Ripat; Alan S Livingstone; Danny Sleeman; Nipun Merchant; Danny Yakoub
Journal:  J Gastrointest Surg       Date:  2017-03-02       Impact factor: 3.452

Review 5.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

Review 6.  Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

7.  Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.

Authors:  Sonya Park; Ashwin Singh Parihar; Lisa Bodei; Thomas A Hope; Nadine Mallak; Corina Millo; Kalpna Prasad; Don Wilson; Katherine Zukotynski; Erik Mittra
Journal:  J Nucl Med       Date:  2021-07-22       Impact factor: 11.082

8.  A rare case of metastasized non-functional pancreatic neuroendocrine tumor with a good long-term survival.

Authors:  A Mirică; I A Bădărău; R Mirică; S Păun; D L Păun
Journal:  J Med Life       Date:  2016 Oct-Dec

Review 9.  Non-functioning pancreatic neuroendocrine tumors: Surgery or observation?

Authors:  Yehonatan Bar-Moshe; Haggi Mazeh; Simona Grozinsky-Glasberg
Journal:  World J Gastrointest Endosc       Date:  2017-04-16

10.  Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.

Authors:  Vincenzo Villani; Krishnan K Mahadevan; Matteo Ligorio; Carlos Fernández-Del Castillo; David T Ting; Francesco Sabbatino; Irene Zhang; Mark Vangel; Soldano Ferrone; Andrew L Warshaw; Keith D Lillemoe; Jennifer Wargo; Vikram Deshpande; Cristina R Ferrone
Journal:  Ann Surg Oncol       Date:  2016-03-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.